Colorectal Cancer (CRC)SURINCT06879873
MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)(SURVEILLANCE-I)
An observational study of Colorectal Cancer (CRC), run by Fudan University.
Trial summary
This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with stage I-III operable colon adenocarcinoma. MRD refers to the presence of cancer cells that remain in the body after treatment but are undetectable by traditional imaging methods. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Colorectal Cancer (CRC)
- How many people
- 390 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2025to 31 Jul 2029
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of patients diagnosed with stage I-III resectable colon adenocarcinoma who have not received prior treatment. Participants will be recruited from multiple clinical centers and must meet specific eligibility criteria to ensure the study's validity. Key Characteristics of the Study Population: Diagnosis: Histologically confirmed colon adenocarcinoma (including adenocarcinoma, mucinous adenocarcinoma, signet-ring cell carcinoma, and undifferentiated carcinoma; excluding adenosquamous carcinoma). Stage: Clinical stage I-III, confirmed by preoperative imaging and clinical assessment. Treatment History: No prior chemotherapy, radiotherapy, targeted therapy, or other anti-cancer treatments. Surgical Eligibility: Candidates must be eligible for curative-intent surgery. General Health Status: ECOG performance status 0-1, indicating good functional status. Age Range: 18 to 80 years old. Consent \& Compliance: Participants must provide informed consent and be willing
Who may be able to join
- Age range: 18-80 years old, male or female not limited;
- Histologically confirmed colon adenocarcinoma (i.e. adenocarcinoma, including adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, undifferentiated carcinoma; excluding adenosquamous cell carcinoma);
- Preoperative staging of stages I-III, without undergoing endoscopic ESD or EMR surgical resection;
- Not receiving chemotherapy, radiotherapy, targeted therapy, or other anti-tumor treatments;
- Radical surgery can be performed;
- ECOG score 0-1 points;
- The subjects voluntarily joined this study and signed an informed consent form, demonstrating good compliance and actively cooperating to return to the hospital for regular clinical follow-up diagnosis and treatment.
Who cannot join
- Previously suffered from other malignant tumors (including non adenocarcinoma colorectal cancer);
- Pregnant and lactating women;
- According to the researchers' assessment, the patient also suffers from other diseases that may affect follow-up and short-term survival
- Subjects have other factors that may lead to the forced termination of this study, such as other serious diseases (including mental illness, infectious diseases, fever ≥ 38 ℃, etc.) requiring combined treatment, serious laboratory examination abnormalities, accompanied by family or social factors, which will affect the safety of subjects, or the collection of data and samples.
About this study
Official title: MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)
This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with stage I-III operable colon adenocarcinoma. MRD refers to the presence of cancer cells that remain in the body after treatment but are undetectable by traditional imaging methods. The study will use a blood-based test to detect circulating tumor DNA (ctDNA) and assess its ability to predict cancer recurrence and survival outcomes.
Patients who are newly diagnosed with stage I-III colon adenocarcinoma and are eligible for surgery will be enrolled. Blood samples will be collected at multiple time points, including before surgery, after surgery, and during follow-up visits over three years. The study will compare MRD status with recurrence-free survival (RFS), overall survival (OS), and the time it takes for MRD to detect recurrence compared to standard imaging methods.
The goal is to determine whether MRD monitoring can provide early warning of cancer recurrence and help guide treatment decisions. This study may offer valuable insights into improving postoperative surveillance and personalized treatment strategies for colon cancer patients.
Read the detailed description
This is a multicenter, prospective, observational study designed to evaluate the effectiveness of ctDNA-based MRD monitoring in predicting disease recurrence and survival outcomes in patients with stage I-III operable colon adenocarcinoma. The study will enroll 390 patients who have not previously received chemotherapy, radiotherapy, or targeted therapy.
Key Objectives:
Primary Objective:
To explore the correlation between MRD status and recurrence-free survival (RFS) in stage I-III colon adenocarcinoma patients.
Secondary Objectives:
To assess the relationship between MRD status and 1-year/2-year recurrence-free survival (1yRFS, 2yRFS).
To evaluate the association between MRD status and overall survival (OS).
Exploratory Objective:
To determine the average time by which MRD detection precedes imaging-based detection of disease recurrence.
Study Design:
Patients will undergo blood sampling at baseline (pre-surgery), post-surgery (7±2 days), and during follow-up visits at 1, 3, 6, 9, 12, 18, 24, and 36 months.
MRD status will be assessed using ctDNA methylation-based PCR technology, which offers a rapid and cost-effective alternative to traditional NGS-based methods.
Statistical Analysis:
The study will use Kaplan-Meier survival analysis to estimate RFS and OS.
Cox regression models will be employed to determine whether MRD status can serve as a prognostic factor for disease recurrence.
Ethical Considerations:
The study adheres to the principles of the Declaration of Helsinki and Chinese Good Clinical Practice (GCP) guidelines.
Informed consent will be obtained from all participants, and their privacy and confidentiality will be strictly maintained.
Expected Outcomes:
The study aims to validate the clinical utility of ctDNA-based MRD monitoring in predicting recurrence and survival outcomes, potentially offering a more effective tool for postoperative surveillance and treatment planning in colon cancer patients.
- Conditions
- Colorectal Cancer (CRC)
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| MRD-Guided Surveillance of I-III CRC | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exploring the correlation between MRD status and disease recurrence rate (RFS) in stage I-III operable colon adenocarcinoma
Exploring the correlation between MRD status and disease recurrence rate (RFS) in stage I-III operable colon adenocarcinoma
Measured: From surgery until disease recurrence or up to 36 months, whichever occurs first
Secondary outcomes (3)
The correlation between MRD status and 1-year recurrence free survival (1yRFS)
The correlation between MRD status and 1-year recurrence free survival (1yRFS)
Measured: From surgery until 12 months post-surgery
The correlation between MRD status and 2-year recurrence free survival (2yRFS)
The correlation between MRD status and 2-year recurrence free survival (2yRFS)
Measured: From surgery until 24 months post-surgery
The correlation between MRD status and overall survival (OS)
The correlation between MRD status and overall survival (OS)
Measured: From surgery until death or up to 36 months, whichever occurs first
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2025
- Study start1 Aug 2025 (estimated)
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal Cancer (CRC)Studies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 390 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xu jianmin, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06879873
- Sponsor's protocol ID
- SURVEILLANCE-I
- Acronym
- SURI
- Status last verified
- Mar 2025
- First submitted
- 11 Mar 2025
- Last updated
- 17 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)
- ClinicalTrials.gov ID
- NCT06879873
- Acronym / sponsor ID
- SURI / SURVEILLANCE-I
- Conditions
- Colorectal Cancer (CRC)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 390 participants (estimated)
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jul 2029 (estimated)
- First posted
- 17 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with stage I-III operable colon adenocarcinoma. MRD refers to the presence of cancer cells that remain in the body after treatment but are undetectable by traditional imaging methods. The study will use a blood-based test to detect circulating tumor DNA (ctDNA) and assess its ability to predict cancer recurrence and survival outcomes.
Patients who are newly diagnosed with stage I-III colon adenocarcinoma and are eligible for surgery will be enrolled. Blood samples will be collected at multiple time points, including before surgery, after surgery, and during follow-up visits over three years. The study will compare MRD status with recurrence-free survival (RFS), overall survival (OS), and the time it takes for MRD to detect recurrence compared to standard imaging methods.
The goal is to determine whether MRD monitoring can provide early warning of cancer recurrence and help guide treatment decisions. This study may offer valuable insights into improving postoperative surveillance and personalized treatment strategies for colon cancer patients.
Detailed description
This is a multicenter, prospective, observational study designed to evaluate the effectiveness of ctDNA-based MRD monitoring in predicting disease recurrence and survival outcomes in patients with stage I-III operable colon adenocarcinoma. The study will enroll 390 patients who have not previously received chemotherapy, radiotherapy, or targeted therapy.
Key Objectives:
Primary Objective:
To explore the correlation between MRD status and recurrence-free survival (RFS) in stage I-III colon adenocarcinoma patients.
Secondary Objectives:
To assess the relationship between MRD status and 1-year/2-year recurrence-free survival (1yRFS, 2yRFS).
To evaluate the association between MRD status and overall survival (OS).
Exploratory Objective:
To determine the average time by which MRD detection precedes imaging-based detection of disease recurrence.
Study Design:
Patients will undergo blood sampling at baseline (pre-surgery), post-surgery (7±2 days), and during follow-up visits at 1, 3, 6, 9, 12, 18, 24, and 36 months.
MRD status will be assessed using ctDNA methylation-based PCR technology, which offers a rapid and cost-effective alternative to traditional NGS-based methods.
Statistical Analysis:
The study will use Kaplan-Meier survival analysis to estimate RFS and OS.
Cox regression models will be employed to determine whether MRD status can serve as a prognostic factor for disease recurrence.
Ethical Considerations:
The study adheres to the principles of the Declaration of Helsinki and Chinese Good Clinical Practice (GCP) guidelines.
Informed consent will be obtained from all participants, and their privacy and confidentiality will be strictly maintained.
Expected Outcomes:
The study aims to validate the clinical utility of ctDNA-based MRD monitoring in predicting recurrence and survival outcomes, potentially offering a more effective tool for postoperative surveillance and treatment planning in colon cancer patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MRD-Guided Surveillance of I-III CRC | – | – |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of patients diagnosed with stage I-III resectable colon adenocarcinoma who have not received prior treatment. Participants will be recruited from multiple clinical centers and must meet specific eligibility criteria to ensure the study's validity. Key Characteristics of the Study Population: Diagnosis: Histologically confirmed colon adenocarcinoma (including adenocarcinoma, mucinous adenocarcinoma, signet-ring cell carcinoma, and undifferentiated carcinoma; excluding adenosquamous carcinoma). Stage: Clinical stage I-III, confirmed by preoperative imaging and clinical assessment. Treatment History: No prior chemotherapy, radiotherapy, targeted therapy, or other anti-cancer treatments. Surgical Eligibility: Candidates must be eligible for curative-intent surgery. General Health Status: ECOG performance status 0-1, indicating good functional status. Age Range: 18 to 80 years old. Consent \& Compliance: Participants must provide informed consent and be willing
Key inclusion criteria (7 listed)
- Age range: 18-80 years old, male or female not limited;
- Histologically confirmed colon adenocarcinoma (i.e. adenocarcinoma, including adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, undifferentiated carcinoma; excluding adenosquamous cell carcinoma);
- Preoperative staging of stages I-III, without undergoing endoscopic ESD or EMR surgical resection;
- Not receiving chemotherapy, radiotherapy, targeted therapy, or other anti-tumor treatments;
- Radical surgery can be performed;
Key exclusion criteria (4 listed)
- Previously suffered from other malignant tumors (including non adenocarcinoma colorectal cancer);
- Pregnant and lactating women;
- According to the researchers' assessment, the patient also suffers from other diseases that may affect follow-up and short-term survival
- Subjects have other factors that may lead to the forced termination of this study, such as other serious diseases (including mental illness, infectious diseases, fever ≥ 38 ℃, etc.) requiring combined treatment, serious laboratory examination abnormalities, accompanied by family or social factors, which will affect the safety of subjects, or the collection of data and samples.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Exploring the correlation between MRD status and disease recurrence rate (RFS) in stage I-III operable colon adenocarcinoma
Time frame: From surgery until disease recurrence or up to 36 months, whichever occurs first
Exploring the correlation between MRD status and disease recurrence rate (RFS) in stage I-III operable colon adenocarcinoma
3 secondary outcomes
The correlation between MRD status and 1-year recurrence free survival (1yRFS)
Time frame: From surgery until 12 months post-surgery
The correlation between MRD status and 2-year recurrence free survival (2yRFS)
Time frame: From surgery until 24 months post-surgery
The correlation between MRD status and overall survival (OS)
Time frame: From surgery until death or up to 36 months, whichever occurs first
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer (CRC)
RecruitingObservational study
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Solid Tumor, Adult, Colorectal Cancer
RecruitingPhase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
RecruitingObservational study
ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort
HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)
RecruitingPhase 1
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
Not yet recruitingPhase 2/3
OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
Cachexia; Cancer, Cachexia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer (CRC), run by Fudan University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exploring the correlation between MRD status and disease recurrence rate (RFS) in stage I-III operable colon adenocarcinoma (time frame: From surgery until disease recurrence or up to 36 months, whichever occurs first). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2025; AzTrials last refreshed its copy on 26 Oct 2026.